Personalized Medicine

Brussels—A simple genetic test using only 3 genes is among the most effective means of classifying breast cancer into the subtypes that indicate pa tients’ different prognoses and response or resistance to cancer therapies, say researchers, and this finding could allow greater use of personalized treatments in breast cancer.

There’s no question that when, on March 29, a federal district court judge ruled the patents held by Myriad Genetics to the BRCA1 and 2 gene mutation sequences are invalid, a shock went through the healthcare and genetics communities.